Product Information
LUBIPROSTONE 24 MCG CAPSULE is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.6507 per EA under NDC 31722040460. Its NADAC has been published 54 times since Sep 24, 2025.
FDA first approved this application on Jan 2, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.024 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722040460
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LUBIPROSTONEApproval Type
Generic (ANDA)
FDA Application
ANDA218640FDA Approved
1/2/2025
TE Code
AB
On Market Since
5/27/2025
Pharmacological Classes
Price Statistics
The NADAC for LUBIPROSTONE 24 MCG CAPSULE has been published 54 times since Sep 24, 2025, and over the history we have for it it has declined 21.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6507 per EA |
|---|---|
| All-time high | $0.8250 (Oct 15, 2025) |
| All-time low | $0.6239 (Aug 19, 2026) |
| 52-week high | $0.8250 |
| 52-week low | $0.6239 |
| Median price | $0.6977 |
| Average price | $0.7193 |
| Largest weekly change | -5.9% (Mar 18, 2026) |
| Weeks tracked | 54 |
| Tracking since | Sep 24, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lubiprostone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Chloride Channel Activator class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LUBIPROSTONE 24 MCG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LUBIPROSTONE 24 MCG CAPSULE, manufactured by Camber Pharmaceuticals Inc., is $0.6507 per EA (NDC 31722040460), effective Sep 30, 2026.
How has the price of LUBIPROSTONE 24 MCG CAPSULE changed over time?
Over the history we have for it, the NADAC for LUBIPROSTONE 24 MCG CAPSULE has declined 21.1%. It has been tracked across 54 weekly CMS publications since Sep 24, 2025.
What are the highest and lowest recorded NADAC prices for LUBIPROSTONE 24 MCG CAPSULE?
Since Sep 24, 2025, the NADAC for LUBIPROSTONE 24 MCG CAPSULE has ranged from a low of $0.6239 (Aug 19, 2026) to a high of $0.8250 (Oct 15, 2025), with a median of $0.6977 per EA.
Are there cheaper alternatives to LUBIPROSTONE 24 MCG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as LUBIPROSTONE 24 MCG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures LUBIPROSTONE 24 MCG CAPSULE?
LUBIPROSTONE 24 MCG CAPSULE (NDC 31722040460) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.